A detailed history of Susquehanna International Group, LLP transactions in Altimmune, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 926,962 shares of ALT stock, worth $7.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
926,962
Previous 2,210,401 58.06%
Holding current value
$7.05 Million
Previous $14.7 Million 61.28%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.5 - $8.1 $7.06 Million - $10.4 Million
-1,283,439 Reduced 58.06%
926,962 $5.69 Million
Q2 2024

Aug 15, 2024

BUY
$5.91 - $10.23 $7.65 Million - $13.2 Million
1,294,147 Added 141.24%
2,210,401 $14.7 Million
Q1 2024

May 07, 2024

BUY
$8.22 - $13.81 $1.5 Million - $2.53 Million
183,000 Added 24.96%
916,254 $9.33 Million
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $1.33 Million - $7.2 Million
619,488 Added 544.53%
733,254 $8.25 Million
Q3 2023

Nov 14, 2023

SELL
$2.4 - $3.45 $156,604 - $225,119
-65,252 Reduced 36.45%
113,766 $295,000
Q2 2023

Aug 11, 2023

SELL
$3.45 - $5.97 $2.13 Million - $3.69 Million
-617,704 Reduced 77.53%
179,018 $631,000
Q1 2023

May 16, 2023

BUY
$4.19 - $16.83 $1.86 Million - $7.48 Million
444,649 Added 126.29%
796,722 $3.36 Million
Q4 2022

Feb 14, 2023

BUY
$8.74 - $16.45 $1.55 Million - $2.91 Million
176,786 Added 100.86%
352,073 $5.79 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $1.87 Million - $3.93 Million
175,287 New
175,287 $2.24 Million
Q1 2022

May 16, 2022

SELL
$5.9 - $9.45 $67,448 - $108,032
-11,432 Reduced 8.37%
125,219 $763,000
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $444,702 - $638,651
51,174 Added 59.87%
136,651 $1.25 Million
Q3 2021

Nov 15, 2021

SELL
$8.43 - $16.81 $624,873 - $1.25 Million
-74,125 Reduced 46.44%
85,477 $967,000
Q2 2021

Aug 11, 2021

SELL
$9.85 - $16.46 $1.67 Million - $2.79 Million
-169,382 Reduced 51.49%
159,602 $1.57 Million
Q1 2021

May 17, 2021

BUY
$12.71 - $24.31 $56,966 - $108,957
4,482 Added 1.38%
328,984 $4.65 Million
Q4 2020

Feb 16, 2021

BUY
$7.84 - $14.22 $1.68 Million - $3.05 Million
214,753 Added 195.68%
324,502 $3.66 Million
Q3 2020

Nov 16, 2020

BUY
$9.93 - $33.26 $911,305 - $3.05 Million
91,773 Added 510.53%
109,749 $1.45 Million
Q4 2019

Feb 14, 2020

SELL
$1.53 - $2.15 $3,935 - $5,529
-2,572 Reduced 12.52%
17,976 $34,000
Q3 2019

Nov 14, 2019

SELL
$1.95 - $2.66 $54,835 - $74,801
-28,121 Reduced 57.78%
20,548 $40,000
Q2 2019

Aug 16, 2019

BUY
$2.19 - $3.4 $440 - $683
201 Added 0.41%
48,669 $116,000
Q2 2019

Aug 14, 2019

SELL
$2.19 - $3.4 $19,911 - $30,912
-9,092 Reduced 15.8%
48,468 $115,000
Q1 2019

May 15, 2019

BUY
$2.54 - $4.54 $146,202 - $261,322
57,560 New
57,560 $167,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $373M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.